268 related articles for article (PubMed ID: 19852561)
1. Trichloroethylene risk assessment: a review and commentary.
Jollow DJ; Bruckner JV; McMillan DC; Fisher JW; Hoel DG; Mohr LC
Crit Rev Toxicol; 2009; 39(9):782-97. PubMed ID: 19852561
[TBL] [Abstract][Full Text] [Related]
2. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
Bogen KT; Gold LS
Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
[TBL] [Abstract][Full Text] [Related]
3. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene.
Liao KH; Tan YM; Clewell HJ
Risk Anal; 2007 Oct; 27(5):1223-36. PubMed ID: 18076492
[TBL] [Abstract][Full Text] [Related]
4. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly.
Evans MV; Chiu WA; Okino MS; Caldwell JC
Toxicol Appl Pharmacol; 2009 May; 236(3):329-40. PubMed ID: 19249323
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation.
Li T; Schultz I; Keys DA; Campbell JL; Fisher JW
Toxicology; 2008 Mar; 245(1-2):35-48. PubMed ID: 18242812
[TBL] [Abstract][Full Text] [Related]
6. Trichloroacetic acid: updated estimates of its bioavailability and its contribution to trichloroethylene-induced mouse hepatomegaly.
Chiu WA
Toxicology; 2011 Jul; 285(3):114-25. PubMed ID: 21549800
[TBL] [Abstract][Full Text] [Related]
7. Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene.
Clewell HJ; Andersen ME
Crit Rev Toxicol; 2004; 34(5):385-445. PubMed ID: 15560567
[TBL] [Abstract][Full Text] [Related]
8. A review of analytical methods for the determination of trichloroethylene and its major metabolites chloral hydrate, trichloroacetic acid and dichloroacetic acid.
Delinsky AD; Bruckner JV; Bartlett MG
Biomed Chromatogr; 2005 Oct; 19(8):617-39. PubMed ID: 15828053
[TBL] [Abstract][Full Text] [Related]
9. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice.
Abbas R; Fisher JW
Toxicol Appl Pharmacol; 1997 Nov; 147(1):15-30. PubMed ID: 9356303
[TBL] [Abstract][Full Text] [Related]
10. Have animal data been used inappropriately to estimate risks to humans from environmental trichloroethylene?
Steinberg AD; DeSesso JM
Regul Toxicol Pharmacol; 1993 Oct; 18(2):137-53. PubMed ID: 8278637
[TBL] [Abstract][Full Text] [Related]
11. Role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver.
Laughter AR; Dunn CS; Swanson CL; Howroyd P; Cattley RC; Corton JC
Toxicology; 2004 Oct; 203(1-3):83-98. PubMed ID: 15363585
[TBL] [Abstract][Full Text] [Related]
12. Duration adjustment of acute exposure guideline level values for trichloroethylene using a physiologically-based pharmacokinetic model.
Boyes WK; Evans MV; Eklund C; Janssen P; Simmons JE
Risk Anal; 2005 Jun; 25(3):677-86. PubMed ID: 16022699
[TBL] [Abstract][Full Text] [Related]
13. Difficulty of mode of action determination for trichloroethylene: An example of complex interactions of metabolites and other chemical exposures.
Caldwell JC; Keshava N; Evans MV
Environ Mol Mutagen; 2008 Mar; 49(2):142-54. PubMed ID: 17973308
[TBL] [Abstract][Full Text] [Related]
14. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
15. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites.
Hack CE; Chiu WA; Jay Zhao Q; Clewell HJ
Regul Toxicol Pharmacol; 2006 Oct; 46(1):63-83. PubMed ID: 16889879
[TBL] [Abstract][Full Text] [Related]
16. Consideration of the target organ toxicity of trichloroethylene in terms of metabolite toxicity and pharmacokinetics.
Davidson IW; Beliles RP
Drug Metab Rev; 1991; 23(5-6):493-599. PubMed ID: 1802654
[TBL] [Abstract][Full Text] [Related]
17. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol.
Fisher JW; Mahle D; Abbas R
Toxicol Appl Pharmacol; 1998 Oct; 152(2):339-59. PubMed ID: 9853003
[TBL] [Abstract][Full Text] [Related]
18. Characterization of presystemic elimination of trichloroethylene and its nonlinear kinetics in rats.
Lee KM; Bruckner JV; Muralidhara S; Gallo JM
Toxicol Appl Pharmacol; 1996 Aug; 139(2):262-71. PubMed ID: 8806842
[TBL] [Abstract][Full Text] [Related]
19. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.
Keys DA; Bruckner JV; Muralidhara S; Fisher JW
Toxicol Sci; 2003 Nov; 76(1):35-50. PubMed ID: 12915716
[TBL] [Abstract][Full Text] [Related]
20. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes.
Haddad S; Tardif GC; Tardif R
J Toxicol Environ Health A; 2006 Dec; 69(23):2095-136. PubMed ID: 17060096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
